Skip to main content

ADVERTISEMENT

Suresh Durgam, MD

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...
10/08/2020
10/08/2020
11/22/2019
Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...
11/22/2019
This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of lumateperone 42mg for the treatment of a major depressive episode in patients with major de...
10/26/2023